Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Confirms Trial Weighted Towards Overall Survival Endpoint

 
• By Andrew McConaghie
  
Roche
The leader in the TIGIT inhibitor field, Roche is banking on the SKYSCRAPER 1 study results turning positive at its next analysis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category